The oncology impact of highly active antiretroviral therapy

about

The oncology impact of highly active antiretroviral therapy

Item

http://www.wikidata.org/entity/Q57832203

description

im März 2007 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 March 2007

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2007

@uk

name

The oncology impact of highly active antiretroviral therapy

@en

The oncology impact of highly active antiretroviral therapy

@nl

type

Item

label

The oncology impact of highly active antiretroviral therapy

@en

The oncology impact of highly active antiretroviral therapy

@nl

prefLabel

The oncology impact of highly active antiretroviral therapy

@en

The oncology impact of highly active antiretroviral therapy

@nl

P1476

The oncology impact of highly active antiretroviral therapy

@en

P2093

Carole Chambers

http://www.w3.org/2001/XMLSchema#string

Richard Schlichemeyer

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

AIDS-associated cancer in developing nations.

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.

Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Antitumour effects of antiretroviral therapy.

The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.

Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

P304

17-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155206074045

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael John Gill

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17621563

http://www.w3.org/2001/XMLSchema#string